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ABSTRACT

Effect of Chronic Administration of Oxytocin on Corpus Luteum Function in Cycling
Mares
by
Katherine Clissold Parkinson, Master of Science
Utah State University, 2016

Major Professor: Dr. Dirk K. Vanderwall
Department: Animal, Dairy, and Veterinary Sciences

Undesirable and variable behavior in mares related to the estrous cycle is a
common issue reported in the equine industry, especially for mares in a performance
setting. These behaviors can interfere with, as well as decrease, overall performance.
The objective of this study was to determine if administration of sixty units of oxytocin
once daily for 29 days, regardless of when treatment was initiated during the estrous
cycle, would induce prolonged corpus luteum (CL) function in cycling mares. Mares
were randomly assigned to two groups: 1) saline-treated control (n=7) and 2) oxytocintreated (n=9). Control mares received 3 cc saline and oxytocin-treated mares received
sixty units (3 cc) of oxytocin intramuscularly (IM) for 29 consecutive days. Treatment
was initiated in all mares on the same day, independent of the day of the cycle. Jugular
blood samples for determination of progesterone concentration were collected three times
weekly (M, W, F) for 21 days before treatment was initiated. Beginning on the first day
of treatment, blood samples were collected daily for seven days, three times weekly for
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the remainder of the treatment period, and then three times weekly for 45 days after the
last treatment. Mares were considered to have prolonged CL function if serum
progesterone remained >1.0 ng/mL for at least 30 days during/after the treatment period.
The proportion of mares with prolonged CL function was higher in the oxytocin-treated
group compared to the saline-treated group (7/9 vs. 1/7, respectively; P<0.05). Three of
the seven oxytocin-treated mares that developed prolonged CL function initially
underwent luteolysis within three to seven days of the start of oxytocin treatment, and
then developed prolonged CL function following the subsequent ovulation during the
treatment period. In the other four oxytocin-treated mares that developed prolonged CL
function, progesterone remained >1.0 ng/mL throughout the treatment period and into the
post-treatment period. All mares with prolonged CL function maintained elevated
progesterone concentrations through at least day 56 of the study. Sixty units of
exogenous oxytocin treatment for 29 consecutive days was effective in prolonging CL
function as a means of estrus suppression in mares.
(78 pages)
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PUBLIC ABSTRACT
Effect of Chronic Administration of Oxytocin on Corpus Luteum Function in Cycling
Mares
by
Katherine Clissold Parkinson, Master of Science
Utah State University, 2016

Undesirable and variable behavior in mares related to the reproductive cycle is a
common issue reported in the equine industry, especially for female horses in a
performance setting. These behaviors can interfere with and decrease, overall
performance. The objective of this study was to determine if administration of 60 units
of the hormone oxytocin once daily for 29 days, regardless of when treatment was
initiated during the estrous cycle, would induce prolonged corpus luteum function in
cycling mares. Mares were randomly assigned to two groups: 1) saline-treated control
(n=7) and 2) oxytocin-treated (n=9). Control mares received 3 cc saline and oxytocintreated mares received 60 units (3 cc) of oxytocin intramuscularly for 29 consecutive
days. Treatment was initiated in all mares on the same day (day 1), independent of the
day of the cycle. Jugular blood samples for determination of progesterone concentration
were collected three times weekly (M, W, F) for 21 days before treatment was initiated.
Beginning on the first day of treatment, blood samples were collected daily for seven
days, three times weekly for the remainder of the treatment period, and then three times
weekly for 45 days after the last treatment. Mares were considered to have prolonged CL
function if serum progesterone remained >1.0 ng/mL for at least 30 days during/after the
treatment period. The proportion of mares with prolonged CL function was higher in the
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oxytocin-treated group compared to the saline-treated group (7/9 vs. 1/7, respectively;
P<0.05). Three of the seven oxytocin-treated mares that developed prolonged CL
function initially underwent luteolysis within three to seven days of the start of oxytocin
treatment, and then developed prolonged CL function following the subsequent ovulation
during the treatment period. In the other four oxytocin-treated mares that developed
prolonged CL function, progesterone remained >1.0 ng/mL throughout the treatment
period and into the post-treatment period. All mares with prolonged CL function
maintained elevated progesterone concentrations through at least day 56 of the study.
Sixty units of exogenous oxytocin treatment for 29 consecutive days was effective in
prolonging CL function as a means of estrus suppression in mares.
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INTRODUCTION
A common complaint of veterinarians, horse owners, and trainers is the variable
behavior and performance of mares that is related to the estrous cycle (Jorgensen et al.,
1996). Because of that, suppression of estrous behavior has become a common practice
in performance mares and the most widely used methods include: 1) administration of
exogenous progesterone/progestins 2) extending the duration of corpus luteum (CL)
function, 3) suppressing ovarian follicular activity, and 4) ovariectomy (Vanderwall and
Nie, 2011). Of these methods, the most commonly used are administration of exogenous
progesterone/progestins and prolonging the life of the CL.
Administration of altrenogest (ReguMate®, Merck Animal Health), an orally
active synthetic progestin, is approved, widely used, and is effective in suppressing
estrous behavior. The use of ReguMate is considered the “gold standard” of estrus
suppression in the equine industry. Unfortunately, the dose of 0.044 milligrams per
kilogram (mg/kg) is needed daily, and other drawbacks such as expense, need for long
term administration, and safety concerns of personnel during handling and dosing are
drawbacks to its use (Squires et al., 1979; Vanderwall, 2012). Another drawback exists
in the fact that because altrenogest is a steroid, it is under increased scrutiny for
administration to animals in performance settings and is not permitted in some countries
(Hedberg et al., 2006). It has been reported that an alternative intramuscular (IM)
administration of compounded preparation of 225 mg, 450 mg, or 500 mg of altrenogest
blocked estrous behavior for 12, 15, and 30 days respectively (Storer et al., 2009).
Compounded products, however, can vary in potency and stability, thus results can also
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vary. The use of a compounded preparation of altrenogest when a Food and Drug
Administration (FDA) approved product such as Regumate ® is available may not be
appropriate, and is not long term enough to be considered an optimal method for estrus
suppression. In an effort to eliminate the inconvenience of daily administration, growthpromoting implants containing progesterone and estradiol labeled for use in cattle have
been anecdotally reported to be effective. When tested in horses under controlled
conditions, the treated horses failed to produce serum progesterone levels above 0.5
nanograms per milliliter (ng/mL) and did not suppress estrous behavior (McCue, 1997).
An alternative to administration of exogenous progesterone and another common
method of estrous suppression is induction of prolonged CL function. This allows for
endogenous secretion of progesterone from the CL to block estrous behavior. In cycling
mares, the CL secretes progesterone for approximately two weeks, during which
progesterone levels are high. The CL stops functioning when prostaglandin F2α
(PGF2α) is secreted by the endometrium during luteolysis (Ginther, 2012). There is
interest in developing methods of prolonging luteal function as a means of estrus
suppression because it allows for the natural secretion of progesterone, rather than the
supplementation of exogenous progesterone/progestins.
There are many methods of inducing prolonged CL function, but the most widely
used method has been insertion of an intrauterine glass ball. In a study by Nie et al.
(2003), placement of a 25-35mm sterile glass ball into the uterus following an ovulation
resulted in prolonged CL function in 7 of 18 (39%) of mares. In the control group, four
of 32 mares (13%) spontaneously prolonged CL function. It is important to note that
while insertion of an intrauterine glass ball seems effective, three of the seven mares in
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the treatment group that prolonged luteal function had one or two estrous cycles after
placement of the glass ball, followed by prolonged CL function. As a result, the “percycle” basis of prolonged CL function was 7/62 cycles (11%) and compared to the 4/50
cycles (8%) in non-treated control mares, and that was not significantly different between
groups. Placement and removal of the intrauterine marble must be done by a veterinarian
when the mare is in late estrus, close to ovulation. Removal must also be done by a
veterinarian, which is a drawback to this method. There have also been reports of
spontaneous fragmentation of the glass ball in the uterine lumen causing deleterious
consequences (LeBlanc, 2011). Because of its variable efficacy, placement of an
intrauterine glass ball does not seem to be a desirable method for suppression of estrus in
mares, thus the need for a safe, practical, and effective method of prolonging CL
function.
There are numerous other methods of estrus suppression, however, each of the
methods has different disadvantages that create a need for more research in the field.
Issues such as cost, reversibility, etc. are also reason for further research. The industry is
in need of a safe, effective, and reliable method of estrus suppression.
Recently, administration of oxytocin has been shown to be an effective method of
prolonging CL function, since administration of 60 units of oxytocin once daily on days 7
to 14 after ovulation induced prolonged CL function in over 60% of treated mares
(Vanderwall et al., 2012b). However, the need to know the exact day of ovulation is a
drawback to the current oxytocin protocol. We hypothesized that by extending the
duration of oxytocin administration, treatment could be initiated at any point during the
estrous cycle (i.e., without knowing the day of ovulation) and still effectively prolong CL
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function. Therefore, the objective of this study was to determine if treating mares with
oxytocin daily for 29 days would result in prolonged CL function.

5
REVIEW OF LITERATURE
The effect of the mare’s estrous cycle on behavior and performance is an
important issue for the equine industry. Specifically, concern over the potential for
estrous behavior to adversely affect performance has led to the common practice of estrus
suppression. Though there are many methods of estrus suppression that are currently
being used, there is a definite need for better options. It is the purpose of this review to
examine the complexities of the equine estrous cycle; its effects on performance and
behavior; and the advantages and disadvantages of the general methods of estrus
suppression that are currently being used. It will also address the need for new options of
estrus suppression and how the use of exogenous oxytocin treatment is effective and
advantageous to the industry.
Estrous Behavior and Performance
Suppression of estrus in mares has become a growing necessity within the equine
industry. The behaviors associated with estrus have been reported to have a negative
effect on the training and showing of horses in many disciplines (McCue, 2003). Today,
horses are expected to perform at a very high level of skill and the horse’s disposition is a
very important factor in its ability to perform (Hedberg et al., 2005). Veterinarians,
trainers, and horse owners all complain of negative performance in mares that is related
to the estrous cycle. A survey of more than 750 veterinarians reflected that
approximately 90% feel that the estrous cycle affected the performance of mares, with the
most frequent clinical sign being reported as a change in attitude. The behaviors
associated with the estrous cycle can include biting, kicking, tail swishing, difficulty to
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train, squealing, “horsing”, excess urination and a decrease in performance (Jorgensen et
al., 1996).
It is important to confirm that the observed behavioral problem is, in fact,
associated with the reproductive cycle of the mare before initiating treatment, as not all of
the previously mentioned behaviors are necessarily associated with estrus. Some
behaviors thought to be associated with estrus can instead be signs of submissive
behavior, stallion-like behavior, or urogenital discomfort (McDonnell, 1993; McDonnell,
2000). Submissive behavior can be mistaken for behaviors related to estrus and usually
include leaning away from perceived threats, squirting urine, and wringing of the tail.
Behaviors truly associated with estrous include leaning towards the stallion, relaxed
lifting motion of the tail, dribbling urine, or a squatting stance (McDonnell, 2000).
Urogenital discomfort can result in behaviors mistaken for estrus, but are typically a
result of cystitis or renal disease instead. Stallion-like behavior may be a result of
neoplasia of the ovaries or the administration of exogenous anabolic steroids
(Vanderwall, 2013). In an effort to correctly diagnose the complaint of estrus-related
behavior or performance issues related to the reproductive cycle, it is important to take
into consideration different factors when determining the source and subsequent
treatment. It is important to determine if the undesirable behavior is from a reproductive
or nonreproductive source followed by determining if the behavior is associated with a
specific phase of the estrous cycle (McDonnell, 2005).
If the behavior can be pinpointed to a specific phase, then determining if the
behavior is physical or behavioral is necessary. Accurate records are needed to aid in
determining the phase of the reproductive cycle during which the behavior occurs. A
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physical examination is also necessary in order to rule out other contributing medical
problems (McCue, 2003). At certain points of the estrous cycle, mares can exhibit
behavior related to pain or discomfort during the preovulatory period. During this period,
the mare has a large ovarian follicle present on the ovary, causing discomfort prior to
ovulation in some mares. This discomfort can cause sensitivity to the weight of a rider
and can vary in severity from subtle to more severe colic-like symptoms (Cox and
DeBowes, 1987; Pryor and Tibary, 2005). The use of an ovulatory agent can be
beneficial for mares experiencing pain due to a large follicle by shortening the time it is
present. (Vanderwall, 2013).
Not all mares have compromised performance from underlying physical causes
during estrus. Some mares have such profound signs of estrus that the behavior alone
affects performance. This can be seen in instances where the animal is under saddle and
displays “break down” behavior showing estrus in response to nearby horses or other
stimuli. This behavior can include a squatting-like pose and the mare will become
difficult to move away from the stimulus (McDonnell, 2000). Behaviors such as this may
not always be evident and can be much subtler. Owners and trainers have reported that
the mare can be simply less attentive or cooperative during estrus, creating difficulty for
training and showing purposes (McDonnell, 1997).
In some cases, mares display abnormal estrous behavior and exhibit signs of
estrus during the anovulatory season, silent estrus, or split estrus. Split estrus can be
defined as a period during normal estrus with alternating days of receptivity to the
stallion. The mare may be receptive one day and non-receptive the next. This is typical
in approximately 5% to 12% of mares (Asa, 1986; Ginther, 1992). Silent estrus is
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characterized by the incidence of ovulation without the subsequent behavior reported in
conjunction with estrus. This phenomenon occurs in 6%-7.5% of the cycles (Cummings,
1942; McCaughey et al., 1973).
There are numerous situations in which the behaviors associated with the estrous
cycle create difficulty for horse owners, trainers, and veterinarians. Some mares become
more difficult than others, and as stated above, there are many situations that differ in
severity. Overall, the effect of ovarian activity in the mare, specifically in the phase of
estrus, has been considered a factor in the decreased performance of the mare (Pryor and
Tibary, 2005). For these circumstances, estrus suppression is recommended.
The Estrous Cycle
In order to better understand the necessity of suppression of some behaviors
related to the estrous cycle, a comprehensive review of mare reproductive anatomy and
physiology, in addition to an explanation of the estrous cycle is warranted.
Anatomy and Physiology
To understand the physiology of the mare’s reproductive system and estrous
cycle, it is important to understand some basics of reproductive anatomy of the horse.
The major female reproductive organs include the ovaries, internal tubular genitalia
(oviducts, uterus, cervix, vagina, and vestibule) and external genitalia (vulva and labia),
as well as the mammary glands. The normal function of these structures is dependent on
hormones and interactions with their appropriate receptor. The neuroendocrine hormones
that are produced or secreted mainly from the hypothalamus and pituitary gland are
especially important. Feedback mechanisms between the central nervous system and
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reproductive organs allow for communication among themselves, thus the endocrine
system plays an important role in regulating and modulating the reproductive events that
occur in the mare (Samper, 2009).
The ovaries include the following structures: follicles, corpora lutea, and oocytes.
These structures are all important to the cyclicity of the mare. During development, the
ovaries develop near the kidneys and have only migrated slightly in adulthood. The
ovaries are approximately 4-8 centimeters (cm) in length, 3-6 cm in width, and 3-5 cm in
height. They lie near the kidneys in the dorsal part of the abdomen, near the iliac wings
of the hip. The left ovary is typically more caudal than the right, a result of the left
kidney also being more caudal. In prepubertal fillies, the ovaries are oval with the cortex
and germinal epithelium being superficial. As the filly approaches puberty, the ovary
transforms into a kidney bean shape. This is a result of the ovarian cortex invaginating
into the medulla (Samper, 2009). The ovaries occur bilaterally, adjacent to the distal end
of each uterine horn.
Within the ovary, structures known as follicles are present. These follicles occur
in a variety of stages including growing, ovulating, anovulatory hemorrhagic, and
regressing. Follicular development in the ovaries occurs in a wave-like fashion through
the different stages of the estrous cycle, seasonal transition, and pregnancy (Ginther,
1992; Ginther et al., 2004)
During the physiological breeding season (i.e., ovulatory season) waves of
follicular development can be classified as major or minor waves, with the major waves
being further classified as primary or secondary. This distinction is based on whether the
largest follicle produced in a wave reaches ≥30 millimeters (mm) or <30 mm. Both
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waves have a growth phase in which a group of follicles begins. Only major waves
display selection of a dominant follicle, while minor waves lack a dominant follicle and,
therefore, no selection. Major primary waves, also known as ovulatory, are associated
with the follicular phase, or estrus. Major secondary waves, which can be ovulatory or
anovulatory, or minor waves are typically associated with the luteal phase, or diestrus.
Mares in transition (spring or fall) will typically display a combination of anovulatory
major follicles and minor follicular waves. In a typical follicular wave during the estrous
cycle, 5-10 follicles (4-6 mm) will develop within 2-3 days of each other. These follicles
will increase in size by 2-4 mm/day until the largest reaches 20-25mm, signaling the end
of the growth phase. Following the growth phase, numerous outcomes can occur. In a
minor wave, all of the follicles will regress, but in the case of a major wave, all but one of
the follicles will regress. As the subordinate follicles decrease in diameter, the dominant
follicle increases in diameter until it ovulates, becomes anovulatory, or regresses
(Samper, 2009).
After ovulation, the process of follicular rupture and release of the oocyte, the site
of the dominant follicle begins to fill in with luteal cells. This process is called
luteinization and involves the morphogenesis of estrogen producing cells of the follicle
into progesterone-producing luteal cells that make up the CL (Figure 1; Ginther, 1992).
The CL plays a significant role in the estrous cycle of the mare, with its main function
being the secretion of progesterone. In non-pregnant mares, the CL secretes progesterone
for approximately two weeks after ovulation, or the duration of diestrus. The CL ceases
function when the endometrium secretes PGF2α and luteolysis occurs (Ginther, 2012).
Artificially induced luteolysis is possible using PGF2α treatment (Samper, 2009).

11

Figure 1. A drawing of a cross section of an ovary (Samper, 2009).
The Estrous Cycle
Mares are considered to be a seasonally polyestrous species and usually have a
20-22 day cycle during the breeding season. During this cycle, 14-15 days are in the
luteal phase, also known as diestrus. Estrus, or the follicular phase, is typically observed
for 5-7 days, but can range in variation from 3-12 days (Pryor and Tibary, 2005).
During the period of estrus, the mare is receptive to the stallion. Behavioral estrus
occurs as a result of the circulating estrogen that is associated with the dominant follicle
being developed in the ovary. Importantly, progesterone is low at this time, as
progesterone overrides the effect of estrogen. The intensity of estrous behavior typically
becomes stronger as ovulation approaches. This phenomenon of behavior corresponds
with physiological events including the dominant follicle reaching maximum size, peak
concentrations of estradiol 1-3 days before ovulation, and endometrial edema. After
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ovulation, estrous behavior will typically decrease simultaneously with the decrease in
circulating estrogen, and the increase of circulating progesterone associated with the
development of the CL occurs. It is typical for estrous behavior to continue for 1-2 days
after ovulation (Samper, 2009).
Ovulation marks the end of one inter-ovulatory interval and the beginning of
another. The time between ovulations is typically referred to as the interovulatory
interval. The day of ovulation is referred to as Day 0 to serve as a point of reference and
aid in the prescription of timed treatments (Samper, 2009).
The ovulatory season typically begins in response to an increase in day length.
This change in light is recognized by photoreceptors in the eye and relayed to the pineal
gland, where changes in melatonin secretion decrease, resulting in increased
gonadotropin releasing hormone (GnRH) synthesis and secretion. GnRH then stimulates
follicle stimulating hormone (FSH) and luteinizing hormone (LH) synthesis via the
pituitary gland, which reaches the ovaries and stimulates follicular growth (Bergfelt,
2009). This interaction is known as the hypothalamic-pituitary-ovarian (HPO) axis
(Figure 2). It is important to understand the HPO axis and the effect it has on
progesterone and estrogen during the estrous cycle.
The high concentrations of circulating estradiol typically peak before ovulation.
These levels of estradiol have a positive feedback on the HPO axis and an increase in LH
during late estrus occurs as a result. The high concentrations of LH that occur are needed
for the dominant follicle to continue growing and also serves as a signal for the coming
ovulation of the follicle (Bergfelt and Adams, 2007). At the time of ovulation, FSH is
low as a result of the negative synergistic effect of inhibin and estradiol (Samper, 2009).
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It will begin to rise as LH and follicular inhibin fall after ovulation. LH is still needed in
low magnitude surges for growth and maturation of the CL and increases circulating
progesterone. Follicle stimulating hormone and progesterone will remain high during
diestrus and the presence of the CL, but will decrease near the end of diestrus as the CL
regresses and undergoes luteolysis (Figure 3).

Figure 2. Seasonal influences on the hormonal and behavioral interactions associated
with the HPO axis (Samper, 2009).

14

Figure 3. Hormonal profiles and associated ovarian activity during the equine estrous
cycle (Samper, 2009)
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Luteolysis

The phenomenon of luteolysis is also known as the cessation of the luteal phase,
or regression of the CL. After day 14 of the mare’s cycle, progesterone levels decrease
dramatically. This event takes place as a result of the pulsatile release of uterine PGF2α.
The combination of the decrease in progesterone and frequent pulses of PGF2α allows
the mechanism of luteolysis to take place. The process of luteolysis is finished by
approximately Day 17 of the mare’s cycle or when progesterone concentrations are <2
ng/mL (Samper, 2009). This typically occurs as a result of the absence of an embryonic
vesicle that otherwise would block a complex mechanism of events leading to the
endometrial secretion of PGF2α and the subsequent disappearance of the CL (Samper,
2009). From an evolutionary standpoint, luteolysis appears to have evolved as a means to
allow mammals to increase their reproductive efficiency. This process allows the animal,
if it did not conceive, to have a short period of time (diestrus) where progesterone is
secreted, resulting in a reduction of cyclic activity and quiescence of the myometrium.
Following this time, the CL is removed via the process of luteolysis, and a new
reproductive cycle can begin (McCracken, 1999).
Uterine Role in Luteolysis
The uterus plays an important role in luteolysis and is responsible for the
mechanisms that allow the CL to persist or regress (Ginther, 1990). Regression of the CL
occurs as a result of pulsatile secretion of PGF2α from the endometrium, which also
brings about the end of diestrus (Alcantara et al., 2005). As previously mentioned, the
decline of progesterone is a hallmark characteristic of luteolysis, as well as the transition
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of the CL into the subsequent structure known as the corpus albicans (McCracken, 1999).
The mechanism of luteolysis has been studied in humans, as well as horses and other
livestock animals. Interestingly, the process of luteolysis is different for each species,
with horses being especially different from other livestock animals. These differences
begin with the pulses of PGF2α, which are measured in the blood by detecting amounts
of the primary systemic metabolite of PGF2α, 13,14-dihydro-15-keto PGF2α (PGFM).
PGFM is measured in the blood as a result of PGF2α having a very short half-life, thus
making it hard to measure, as opposed to PGFM, which is commonly measured in
research settings because it is longer lasting and presents an accurate representation of
circulating PGF2α (Ginther, 2012).
There is a distinct difference in the route of PGF2α transport between mares and
ruminants. The transport of PGF2α from the uterus to the CL in mares differs due to
PGF2α being transported from the uterus to the ovaries via whole-body (i.e., systemic)
circulation, differing from cattle and the local transport and effectiveness of PGF2α via
countercurrent exchange from the utero-ovarian vein to the ovarian artery. This occurs in
ruminants as a result of the venous and lymphatic vessels of the uterine horn passing
along the ovarian pedicle in close proximity to the ovarian artery. PGF2α, which is fat
soluble, passes through the walls of the uterine vessels and the ovarian artery, which are
near each other, thus countercurrent exchange and local delivery of PGF2α to the ovary
and CL, is achieved (Ginther et al., 1972).
Mares, differing from ruminants, do not have the proximity of uterine vessels and
ovarian artery needed in order to achieve counter current exchange of PGF2α. The
ovarian artery lacks major contact with the uterine vein and thus the secretion of PGF2α
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and action on the CL takes place systemically (Ginther et al., 1972). This phenomenon
has been established by various studies, which had the common goal of establishing the
systemic route of PGF2α in the mare. Douglas et al. (1975a) used three different doses of
PGF2α (0, 0.25, or 1.25 mg) and 3 different routes of administration of PGF2α in order to
better understand the luteolytic effect of PGF2α. They found that there was no
significant difference between the administrations of PGF2α locally or systemically.
Ginther and First (1971) found that the CL was maintained despite partial hysterectomy
and no difference in whether the contralateral or ipsilateral tissue to the CL was removed.
Further studies by Ginther included the observation of the unilateral relationship of the
embryo and uterus in ruminant animals versus mares. Mares displayed a relationship
between uterus and embryo that allowed for the CL to be maintained while the embryo
moved to different locations within the uterus. This movement differs from the stationary
location of the embryo in ruminants and further solidified that the unilateral utero-ovarian
relationship and intrauterine effectiveness of PGF2α is effective in ruminants, but not
mares (Ginther et al., 2009)
Role of oxytocin in luteolysis
As previously mentioned, in mares, as well as many other domestic animals,
PGF2α is secreted in a pulsatile fashion during luteolysis. PGF2α is considered to be
responsible for luteolysis in equines and induces luteolysis in both the diestrus period and
early pregnancy in mares (Douglas and Ginther, 1972). The mechanisms that lead to the
secretion of PGF2α release in mares are not fully understood, however, in domestic
ruminants, it is known that the release of PGF2α from the endometrium is induced by the
action of oxytocin, likely from the posterior pituitary, on endometrial oxytocin receptors
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(Silvia et al., 1991). The development of these oxytocin receptors is dependent on the
circulating presence of steroid hormones (Vallet et al., 1990). During late diestrus,
estrogen interacts with the uterus, which has been primed by progesterone, and increases
the amount of oxytocin receptors present (Zhang et al., 1992). The PGF2α that is
secreted as a result of the action of oxytocin from the posterior pituitary then stimulates
the secretion of oxytocin from the corpus luteum (Flint and Sheldrick, 1982). This order
of events creates a positive feedback loop, which subsequently results in an increased
production of PGF2α, creating the characteristic spike in PGF2α needed for luteolysis.
Although it is not fully understood in the equine species, it is thought that oxytocin does
play a role in the luteolytic process in mares.
As research has continued on the role of oxytocin in mares, it has become
generally accepted that oxytocin plays an important role in the secretion of PGF2α. The
origin of oxytocin related to luteolysis in mares is thought to be from the posterior
pituitary (Vanderwall et al., 1998) and/or from the endometrium (Stout et al., 2000), but
not from the CL (Stevenson et al., 1991). The oxytocin secreted from both sources
stimulates the secretion of uterine PGF2α, and additional oxytocin is released in response
to PGF2α, thus creating a positive feedback loop. This positive feedback mechanism is
thought to be involved in the multiple large pulses of PGF2α that are observed during
luteolysis (Stout, 2011).
It has been found that each pulse of PGF2α during luteolysis is also associated
with a pulse of oxytocin, which supports the general consensus that oxytocin plays a key
role in equine luteolysis (Ginther and Beg, 2009). Other studies that have contributed to
the theory include examples such as Betteridge et al. (1985) who found that oxytocin
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administered during late diestrus results in a rapid increase of plasma PGFM, as well as a
study by Goff et al., (1987) which established that PGFM levels in response to oxytocin
reach a maximum near the time of luteolysis. Subsequent studies demonstrated that the
late diestrus increase in oxytocin responsiveness correlated with an increase in the
binding capacity of endometrial oxytocin receptors (Starbuck et al., 1998; Sharp et al.,
1997).
In nonpregnant mares, there is a corresponding rise in the ability of the
endometrium to secrete PGF2α in response to oxytocin, and an increase in the
concentration of oxytocin receptors at the end of diestrus (Starbuck et al., 1998). Both
are high between days 10-15 post ovulation, however, in contrast to this phenomenon,
prior to day 10, the concentration of endometrial oxytocin receptors and enzymes
necessary for the synthesis of PGF2α are low. The low concentration of receptors
effectively interrupts the ability of enough oxytocin to bind and stimulate PGF2α
secretion (Boerboom et al., 2004).
The development of oxytocin receptors and the ability of the endometrium to then
release PGF2α in response to oxytocin is the first key aspect of luteolysis in the mare.
The second important aspect of luteolysis is the upregulation of enzymes that play a role
in the synthesis of PGF2α (Boerboom et al., 2004). Prostaglandins are produced in
response to a wide variety of stimuli, including oxytocin binding to its receptor, which
ultimately results in the activation of phospholipase A2 (PLA2) that results in the
liberation of arachidonic acid (AA) from membrane phospholipids (Boerboom et al.,
2004). This phenomenon generates the substrate necessary for PGF2α synthesis (Keith et
al., 2013).
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Oxytocin receptor activation also plays a role in the activation of mitogenactivated protein kinase, which is important in the regulation of cyclooxygenase gene
expression (Molnar et al., 1999; Soloff et al., 2000). These cyclooxygenase enzymes are
rate-limiting enzymes for prostaglandin synthesis and occur in two forms.
Cyclooxygenase 1 (COX-1) and cyclooxygenase-2 (COX-2) both work downstream of
PLA2 and convert arachidonic acid to prostaglandin G2 and H2. Prostaglandin H2 can then
be converted into PGF2α by prostaglandin F synthase (PGFS) in the uterus (Keith et al.,
2013).
COX-2 appears to be more heavily involved in the mechanisms of luteolysis and
maternal recognition of pregnancy than COX-1. In both cows and sheep, COX-2
expression was found in late diestrus, occurring around the time of luteolysis, however,
COX-1 was minimally found in sheep and undetectable in cows (Charpigny et al., 1997;
Arosh et al., 2002) While COX-2 is strongly expressed around the time of luteolysis, this
phenomenon does not occur during pregnancy in the mare. This suggests that the equine
conceptus somehow blocks the synthesis of PGF2α in the endometrium by repressing
COX-2 expression. It appears that the prevention of luteolysis depends on the inhibition
of COX-2 expression and the decrease of oxytocin receptors (Boerboom et al., 2004).
Understanding the complex role of oxytocin in equine luteolysis and pregnancy is
important for the use of oxytocin in preventing luteolysis. Preventing the termination of
the CL through understanding the interactions of oxytocin is key for the use of oxytocin
as a route to prolong CL function in mares.
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Prolonged Luteal Function
The condition of prolonged luteal function can occur spontaneously in the mare,
creating a difficult challenge in mare reproduction. As previously reviewed, the
luteolytic event is characterized by the structural and functional demise of the CL. At
times, and for many reasons, the CL can spontaneously remain present on the ovary
beyond the expected time of luteolysis in a nonpregnant mare. This occurrence is
referred to by many different terms, but all are similar in referring to persistence of the
CL on the ovary.
Prolonged, or persistent luteal activity can occur in mares during approximately 810% of interovulatory intervals during peak ovulatory season. This number increases
significantly during the fall transition period, rising to 25% (King et al., 2010). The
occurrence of persistent luteal function has been associated with a few different uterine
pathologies such as pyometra, as well as with early embryonic loss (Hughes et al., 1979;
Bergfelt et al., 1992). There are instances where the CL is prolonged or persistent
without any obvious reason and, in that situation, is typically referred to as spontaneous
or idiopathic prolonged CL function (Stabenfeldt et al., 1974; Ginther, 1990).
There are a few situations that are thought to be the source of spontaneously
prolonged CL function including the failure of the CL to respond to PGF2α, failure of the
PGF2α to travel to the CL, and failure of the uterus to synthesize PGF2α (Ginther, 1990).
Mares are thought to have prolonged CL function when their progesterone concentrations
are greater than 1.0 ng/mL for at approximately 60 days, although the duration can range
from 35-95 days (Santos et al., 2015).
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While the development of spontaneously prolonged CL function can be
inconvenient and frustrating in equine reproductive biology, it does also serve as a basis
of understanding for prolonging CL function intentionally for the purpose of estrus
suppression. This method would be an effort to use the CL and subsequent progesterone
levels to keep the mare out of normal estrus, and allow the naturally secreted
progesterone to eliminate behaviors associated with estrus. Prolonging CL function is an
excellent option for estrus suppression in equine performance settings and will be
discussed in detail later in this review.
General Methods of Estrus Suppression
Prolonging CL function is not the only method of estrus suppression that is used
within the equine industry. For the purpose of this review, multiple other methods will
be outlined in order to give an overview of the advantages and disadvantages of each.
Previously in this review, the issue of mare performance and behaviors related to
the estrous cycle was addressed. The common complaint of those involved in the
industry has been a factor in the research efforts for estrus suppression. For years,
different methods have been used with varying levels of success. Mares are used often in
the performance industry and the control of their estrous cycles and subsequent behaviors
is warranted. As stated previously, the effect of the estrous cycle, particularly during the
state of estrus, on the performance of mares can be variable, making the showing and use
of these animals difficult or inconvenient.
Over the years, the development of different methods of suppressing estrus has
grown and there are many different avenues to achieve the desired effects. Some
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methods are more effective than others and have led to some techniques being less
frequently used and other, newer techniques developing. Overall, there is a growing need
for the effective control of estrus that will benefit the equine performance industry.
Much research has been dedicated to this topic and it is the purpose of this review to
outline and describe the various methods that are available to suppress estrus in addition
to their effectiveness and safety.
The methods of estrus suppression that exist can be broken down into a few
different categories. Most of these methods fall under the categories of hormonal,
surgical, immunologic, and others methods. It is important to note that mares are unique
animals, differing in many ways from other domestic animals. Previously, this review
has pointed out differences in anatomy and physiology that vary greatly from other
domestic species pertaining to reproduction. Some methods of synchronization or
suppression of estrus used in other species are not necessarily effective in the equine
species. The following methods to be reviewed represent the general body of research
and methods related to estrus suppression in mares.
Hormonal Methods and Methods of Prolonging Function of the CL
Progesterone
The use of exogenous progesterone/progestins has been widely used as a method
of estrus suppression. Staring in the 1960s, Loy et al., (1966) found that intramuscular
injection of 0.2 mg/kg of progesterone oil was effective in suppressing signs of estrus in
mares (Loy and Swan, 1966). Although this was found to be effective and progesterone
in oil is available from pharmacies, it’s need for daily administration and long-term
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injections proved limiting. Progesterone has historically been associated with tissue
reactions at the injection site, making this method undesirable to owners and creating
horses with needle aversions (Pryor and Tibary, 2005). One alternative that developed
was the use of another compounded formulation of progesterone, this time a long-acting
formulation of 1.5 grams (g), which maintained blood progesterone levels above 1.0
ng/mL for approximately 10 days (Vanderwall et al., 2007a). Although this compounded
formula allowed for more time between injections, the potential for soreness at the
injection site was again a limitation for use in performance horses. The long-acting
formulation is also not approved by the FDA, which poses risk to veterinarians and
clients.
Perhaps the most commonly used and successful method of administration of
exogenous progesterone/progestins is altrenogest, an orally active synthetic progestin. It
is FDA approved, and considered the “gold standard” as far as methods used to suppress
estrus in mares. The typical dose is 0.044 mg/kg daily, orally and has been proven to be
effective in suppressing estrus. The altrenogest is most widely known as ReguMate
(Intervet/Merck Animal Health, Summit, NJ), and while it is proven to be effective, one
study found that 76.6% of veterinarians participated in administering altrenogest to
performance mares with an observed decline in performance related to estrus, but only
44% of owners reported it to be successful (80% improvement) (Jorgensen et al., 1996).
This can be related to the ability of mares to maintain follicular activity and possible
ovulation. As a result, mares that display preovulatory pain related to follicles and
ovulation may show continued discomfort despite treatment with altrenogest. Other
disadvantages exist such as the need for daily administration, expense, and the added
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safety concern of personnel during handling and administration (Squires et al., 1979;
Vanderwall, 2012). Alternatively, it has been reported that IM administration of
altrenogest in a compounded formula containing 225 mg or 450 mg of altrenogest with a
sustained-release administration effectively blocked estrous behavior for 12 and 15 days,
respectively. Administration of the 500 mg of altrenogest suppressed estrous behavior
for approximately 30 days (Storer et al., 2009). Although injectable altrenogest appears
effective, it is not an FDA approved method and the compounded products can vary in
potency and stability. This poses difficulties with variable results as well as a problem
for veterinarians who should use FDA approved products (Vanderwall, 2013). In
addition to these disadvantages, another issue exists. Altrenogest is a 17α-allyl derivative
of trenbolone, an anabolic steroid similar to testosterone. Because of the similarities to
anabolic steroids, the use of altrenogest in performance horses is under increased scrutiny
and is considered a doping agent in some countries (Pryor and Tibary, 2005). However,
one study showed that mares treated with altrenogest for the recommended period of
eight weeks did not display any characteristics of anabolic steroids in horses such as
dominance, body mass, or body condition scores compared to control mares (Hodgson et
al., 2005). Other restrictions related to the administration of altrenogest also exist. Longacting progesterone is not permitted by the British Jockey club, the Swedish Trotting
Association, and the International Federation for Equine Sports. In addition to these
restrictions, the use of oral altrenogest is also prohibited for competition horses (Hedberg
et al., 2006).
There have been reports of the use of other synthetic progestins for estrus
suppression in mares, however, none have been found to stand up to rigorous testing and
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still be deemed effective (Vanderwall et al., 2012b). Reportedly, other synthetic
progestins are rather ineffective, so altrenogest remains the most widely used and
successful method of administering exogenous progesterone/progestins, however because
of the many drawbacks, an effective alternative is needed.
Pregnancy
Pregnancy is another means of estrus suppression that has been found to be
effective. This takes advantage of the natural role of the conceptus to effectively block
luteolysis, subsequently maintaining CL function and continuing secretion of
progesterone. In a study by Lefranc and Allen, the establishment of pregnancy, followed
by the manual transrectal rupture of the conceptus between days 16 and 22 of gestation
resulted in 10 of 11 mares (91%) displaying prolonged CL function for at least 60 days.
These mares did not display estrous behavior during that time (Lefranc and Allen, 2004).
A pregnant mare can also be aborted between days 50-60 of gestation and have elevated
progesterone levels for 120 days or more. This is much more difficult than aborting the
fetus at an earlier time. Aborting later, during those particular days of the pregnancy is
effective as a result of the endometrial cups that have developed by that period and the
mare will not return to estrus for approximately 60 days. It is important to note that a
small amount of mares will also display behavioral signs during pregnancy (Nie, 2007).
While pregnancy is an effective method of suspending cyclicity, there are some obvious
disadvantages that may prove undesirable for many horse owners. Factors such as the
cost involved with establishing pregnancy, especially if a foal is undesired, and the ethics
involved with terminating a healthy conceptus may be unacceptable to horse owners
(Vanderwall, 2013).
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Implants
A variety of implants containing progestins, which are labeled for use in other
species, have been used experimentally in mares in an effort to suppress estrus.
Progesterone delivered vaginally through the use of a Controlled Intravaginal Drug
Release (CIDR) has also been used, however, it was not considered to be a useful
method in performance horses (Pryor and Tibary, 2005).
The use of bovine hormonal implants has also been examined for use in mares. In
cattle, the implants are used as weight gain promoters. These implants come in various
forms such as Synovex-C ® (Fort Dodge Animal Health, Overland Park, KS) which
contains 100 mg of progesterone and 10 mg of estradiol benzoate, or Synovex-S ®,
(containing 200 mg of progesterone and 20 mg of estradiol benzoate). The use of these
implants has been frequently talked about and used in equine medicine, and in 1996, a
survey reported that the use of these implants were the second most commonly used
method for estrus suppression. Almost 71% of owners and trainers felt that it was
effective, however, the scientific data shows that the use of these implants is not effective
in suppressing estrus in mares (Jorgensen et al., 1996). The doses of these implants have
even been used in large numbers (up to 80 implants) rather than the labeled dose of eight
pellets. The pellets have been implanted in various regions of the mare’s body including
the pectoral region, under the mane, and in the vulva. Scar tissue and inflammation can
develop at these sites (Nie, 2007). The unsuccessful nature of using these implants is due
to the lack of absorption of progesterone in sufficient quantity (McCue et al., 1997).
Other implants have been studied, such as an implantable norgestomet (Crestar,
Intervet Australia, Bendigo East Victoria, Australia), a pellet that is marketed for estrus

28
suppression in mares, and Levonorgestrel (Norplant, Wyeth, Collegeville, PA), which is
an implantable progestin used as a contraceptive in women. There is la lack of evidence
of valid information regarding dose, frequency, response, or safety of these products.
Another implant that has been examined is Zeranol (Ralgro, Schering-Plough,
Kenilworth, NJ), which is an anabolic agent used for growth stimulation in cattle.
Veterinarians report minimal use for estrus suppression in mares and those that have
administered it used doses ranging from 1-3 pellets (12-36 mg) per mare. All reports
available indicate that Zeranol is ineffective for estrus suppression in mares (Nie, 2007).
The use of deslorelin acetate in the form of an implant known as Ovuplant (Fort
Dodge) has also been used. Deslorelin Acetate is an analogue of GnRH and has been
found to induce ovulation in mares when a follicle of greater than 35 mm in diameter is
present (McKinnon et al., 1993; Mumford et al., 1995). One study showed that upon
implanting a double dose (two 2.1 Ovuplant implants) of deslorelin acetate, most mares
displayed suppressed follicular activity for at least 30 days (McCue et al., 2000). In order
to achieve complete arrest of ovarian activity, Johnson et al., reported that three
deslorelin implants were used, however, these results were not completely reliable.
When mares received three implants, the interovulatory period was extended (36.8 days)
as compared to mares with a single implant (22 days). While it is possible that some
mares are sensitive to down regulation, complete ovarian inactivity was not achieved,
even with three implants (Johnson et al., 2002; Johnson et al., 2003).
It appears that the use of various implants is useful in some situations, with
different products being more successful than others. The need for a method of estrus
suppression that is safe, as well as reliable is still needed.
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Glucocorticoids
There appears to be conflicting reports regarding the effectiveness of
glucocorticoids on suppressing estrus in mares. One group reported that administration
of dexamethasone (30 mg/day) to mares that are on day 10 of the cycle (post-ovulation)
suppressed estrus in seven of eight mares compared to control mares (Asa and Ginther,
1982). The controversy lies in the contrasting report of McKinnon et al., (1997) who
were unable to suppress or prevent follicular development of the estrous cycle when
administering dexamethasome in late estrus. Although there are reports of effective use
of dexamethasone, it is thought that there are potential effects of long-term use that
warrant caution. Veterinarians surveyed reported no use of glucocorticoids to suppress
estrus (Nie, 2007).
Medroxyprogesterone Acetate
The use of other progestins has been examined such as megestrol acetate,
hydroxyprogesterone caproate, and hydroxyprogesterone hexanoate. These progestins
failed to be useful to help maintain pregnancy in the mare, most likely because of the
inability to bind to the progesterone receptor in horses. One long-acting progestin that
has also been examined for equine use is medroxyprogesterone acetate (MPA) better
known in human medicine as Depo-Provera (Pfizer). It is highly successful as a human
contraceptive given every 3 months via injection. It has been found to be effective in
suppressing estrus in queens and bitches, however, it is associated with a high rate of
undesirable side effects (Kutzler and Wood, 2006). The use of MPA in mares has
occurred, but results and effectiveness vary. Gee et al., (2009) found that administration
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of compounded MPA starting on day 7 with 1,600 mg MPA intramuscularly and
continuing with 400 mg on days 14, 21, 28, 35, and 42 had no effect on estrous behavior,
nor follicular development, serum progesterone or LH concentrations.
Induction of a Late-Diestrus Ovulation
Mares, as mentioned earlier, have several differences from females of others
species in various ways. One such difference unique to mares is the ability to ovulate
during diestrus, despite high progesterone concentrations. This phenomenon can happen
in approximately 20% of Thoroughbreds and Quarter Horses during the luteal phase,
however, in ponies, the frequency is very low (Wesson and Ginther, 1981; Hughes et al.,
1985). Spontaneous diestrus ovulations can occur between one to four days prior to
luteolysis and may cause a prolonged luteal phase. This is due to the immature CL being
refractory to prostaglandin (Douglas and Ginther, 1975b). Inducing a late-diestrus
ovulation using human chorionic gonadotropin (hCG) has been explored. Hedberg et al.
(2006) conducted a study during which five treatment mares and four control mares were
monitored starting on day 8 post-ovulation. Using transrectal palpation and ultrasound,
mares were examined until a diestrus follicle greater than 30 mm was found. Treatment
of saline or 3000 units of hCG intramuscularly followed. The mares continued to be
monitored and at the conclusion of the study, three of the four mares that developed a 30
mm follicle and received hCG treatment, ovulated and displayed prolonged luteal phases
lasting 58 to 82 days after treatment.
This method appears successful, however, it is important to note that one mare
never developed a large enough follicle to be treated with hCG. Also, of the mares that
were treated, five of the nine required multiple estrous cycles to develop a follicle large
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enough to be treated (Hedberg et al., 2006). The advantages of this method are
outweighed by the cost and effort made to frequently check the mares to determine
eligibility for treatment, as well as the fact that some mares may take multiple cycles to
develop a suitable follicle or one at all. This does not provide owners with a method that
allows for estrus suppression in a timely manner and further exploration for a safe,
reliable, and effective method are needed.
Intrauterine Infusion of Plant Oils
Intrauterine infusion of plant oils as a method of suppressing estrus is another
avenue that has been explored. A study was published by Wilsher and Allen (2011),
demonstrating that infusion of 10 mg of estradiol in 1 mL of fractionated coconut oil was
effective. Administration on day 6, 8, 10, 12, or 14 post-ovulation resulted in prolonged
CL function in 25%, 75%, 92%, 83%, and 50% of treated mares, respectively. Further
investigation demonstrated that estradiol was not needed for prolonged CL function
because 1 mL fractionated coconut or peanut oil, neither with estradiol, on day 10
resulted in 92% of mares displaying prolonged CL function. It has been hypothesized
that the effectiveness of infusion of plant oils is based on the fatty acid milieus present in
the oils of both plants and the role of modulating synthesis and/or secretion of PGF2α
near the time of luteolysis, thus resulting in prolonged CL function. The infusion of plant
oils appears to be an effective method of suppressing estrus, however, more research on
the topic is needed in an effort to establish safety and long-term effects.
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Intrauterine Device
Placement of an intrauterine device to prolong function of the CL is a common
method of estrus suppression. Nie et al., (2003) found that placement of a 25 or 35 mm
glass ball into the uterus, at the time of ovulation, prolonged CL function in seven of 18
mares (39%) that retained the glass ball. Six of 12 mares quickly expelled the 25 mm
glass ball after insertion. In the mares that developed prolonged CL function for
approximately 90 days, blood progesterone levels did not decline below 1.0 ng/mL and
no estrous behavior was exhibited. In the control group, four of 32 mares (13%)
displayed spontaneously prolonged luteal function, a phenomenon that has been
discussed previously.
This method appears effective in blocking estrus for an extended time, however in
11 mares that retained the glass ball, extended CL function never developed and the
mares continued to cycle normally. In addition, three of the seven mares that received a
glass ball underwent two or three normal estrous cycles prior to displaying prolonged CL
function. Although the use of a glass ball does work, it’s lack of consistency creates a
low rate of success. On a “per cycle” basis, the proportion of mares with prolonged CL
function was only 7/62 cycles (11%) compared to the mares in the control group with
spontaneously prolonged CL function, which was 4/50 cycles (8%) (Nie et al., 2003),
which was not significantly different.
It is plausible the mechanism by which a glass ball facilitates prolonged CL
function is similar to the action of an embryo to prevent luteolysis. The “embryo
mimicking” effect of the presence of the glass ball may interrupt the up-regulation of
endometrial gene expression of the enzyme COX-2, which as discussed previously, plays
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an important role in the synthesis and secretion of PGF2α (Boerboom et al., 2004). In a
study by Rivera del Alamo et al., (2008) the use of an intrauterine device induced
prolonged CL function in 75% of the mares in the study. The higher success rate is could
be attributed to the fact that no uterine treatments were performed after the insertion of
the device, as opposed to Nie et al. (2003) who infused the uterus with 1 g of ticarcillin
disodium in a 35-mL volume, and the fact that Rivera del Alamo, as opposed to Nie, did
not use cloprostenol, which can decrease progesterone levels. Other differences in the
studies related to the size, material, and weight of the devices. The glass balls used by
Nie et al. (2003) had diameters of 25 to 35 mm, making them larger and heavier than the
plastic balls used by Rivera del Alamo et al. which were water filled polypropylene balls
measuring 20 mm in diameter. It was hypothesized that a lighter device might move
within the uterus more and be more effective in inducing prolonged luteal function,
however, there was no significant difference in mobility found. It was concluded, similar
to Nie et al., that the “embryo-mimicking” effect of the intrauterine device prevents the
upregulation of COX-2 (Rivera del Alamo et al., 2008).
A veterinarian must perform the placement and removal of an intrauterine glass
ball. The glass ball is autoclaved for sterilization prior to placement. The mare must be
in late estrus or close to ovulation, with a relaxed cervix for the glass ball to be manually
placed in the uterus by the veterinarian in sterile procedure. The marble is placed
vaginally and pushed through the cervix, followed by location of the glass ball per rectum
and pushed forward into the uterine body. Removal involves the mare to be in peak
estrus, and the glass ball is manipulated toward the cervix then removed (Nie, 2007).
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In the same study by Nie et al., (2003) the use of intrauterine glass balls was
deemed safe. In more recent years, it has been reported that spontaneous fragmentation
as well as irritation, colic, and pyometra has occurred (Klabnick-Bradford, 2013;
Freeman, 2015). Plastic has been used in an effort to reduce this complication, however,
regardless of material used, some mares retain the devices long enough that the presence
of an intrauterine device may not be disclosed when the mare is sold, and anecdotal
reports of mares becoming pregnant regardless of the device and aborting is also a
concern (Vanderwall, 2013).
Because of the variability in effectiveness and the potential for serious
complications, a method with increased reliability and safety, as well as easily reversed is
needed.
Immunologic
GnRH vaccine
As previously reviewed, GnRH plays a pivotal role in equine reproduction.
Ovarian activity is heavily influenced by gonadotropin secretion, which is regulated by
GnRH. The immunization of horses against GnRH has been researched for several years
and numerous studies have taken place to determine the effectiveness of this method.
Vaccination against GnRH results in the induction of anti-GnRH antibody and these
antibodies bind to endogenous GnRH preventing it from stimulating gonadotropin
secretion from the anterior pituitary gland. The binding in this location prevents the
stimulus to gonadotropin secretion and decreases ovarian activity (Pryor and Tibary,
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2005). The use of a GnRH vaccine has been studied in multiple species, from elephants
to humans, with a wide variety of objectives.
The use of the vaccine in wild animals has been shown to be an effective method
of population control (D'Occhio, 1993; Fayrer-Hosken et al., 2000). Applications for
human use includes GnRH vaccine to decrease testosterone levels for treatment of
prostate cancer (Simms et al., 2000). Aside from these uses, the application of the
vaccine in farm animals is the most relevant to this review. It has been shown to be an
alternative to surgical castration and is efficacious in decreasing sexual and aggressive
behavior in cattle, as well as the prevention of pregnancy in pigs (Esbenshade and Britt,
1985; Prendiville et al., 1995; Thompson, 2000).
In horses, the use of GnRH vaccine started as an alternative to castration but soon
evolved into use in mares. In the first studies, ovarian activity and estrous behavior were
not monitored (Garza et al., 1986; Safir et al., 1987). The vaccine was administered with
a primary goal of investigating the effects of GnRH vaccination and the relationship with
gonadotropin secretion. At the cessation of the studies, the mares were either
ovariectomized or the study was terminated and mares were not tracked for normal
cyclicity. Thus, no information was gathered about the safety of the immunization
regarding future reproduction. Later studies found the same treatment effective in six 2year-old fillies and data was collected regarding behavior as well. Both ovarian function
and estrous behavior were suppressed and the fillies returned to normal reproductive
function (Tshewang et al., 1997), however, in mature mares, there was greater variation
in these results, with anestrus lasting up to 15 months in two of three mares vaccinated.
The study also reported that mares with totally inactive ovaries continued to show estrus
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signs with varied duration and variability (Dalin et al., 2002). This is related to the
occurrence of “paradoxical estrus” in mares, which is due to the fact that hormone driven
behavior can originate from locations other than the ovaries, such as the adrenal glands.
This phenomenon is also a factor in the practice of ovariectomy, which is discussed
below.
In a study by Imboden et al. (2006) the primary goal was to investigate the results
of immunization of GnRH and effects on the reproductive tract. The mares were
administered Improvac ® (CSL Limited, Australia), which has been successfully used to
control boar taint in pigs. All nine treatment mares showed an immediate response to the
first vaccine and peak response after the booster injection. Titers reached high levels and
then slowly declined until 100 weeks following the first vaccination, however, as
demonstrated by previous studies, titer can be independent of degree of ovarian
suppression and variable per individual. In spite of suppression of ovarian function, four
mares displayed sporadic estrous behavior and one mare continuously displayed those
behaviors. In addition to variation in titer, resumption of normal cyclicity was variable
and adverse effects such as tissue swelling at the injection site, lameness, and fever were
also reported.
More recently, another GnRH vaccine (EquityTM oestrus control: CSL Animal
Health, Victoria, Australia) was licensed for use in mares in Australia, specifically for
control of estrus. The protocol involves four intramuscular injections of vaccine to the
pectoralis region of muscle. The treatments are staggered with the first injection
administered 10 days post-ovulation, the second injection 20 following the first, and the
third 20 days following that. The fourth injection is administered 30 days after the third
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injection. Immunization resulted in a response of GnRH antibodies in all mares,
however, individual variability in response once again occurred. Also, because the
GnRH is mixed with Equimune ®, which has a strong effect at the injection site,
inflammation and irritation can occur (Pryor and Tibary, 2005)
The use of GnRH vaccine is somewhat effective and eventually reversible,
however, the length of time needed for resumption of cyclicity does not provide a method
that is easily reversible for breeding purposes. The failure of some mares to return to
cyclicity is concerning as well. Most importantly, because of the nature of the adrenal
glands, merely suppressing ovarian activity does not always prevent unwanted estrous
behavior and thus the vaccination against GnRH does not provide a method that is as
predictable or controllable as do other treatments.
Surgical
Ovariectomy
Ovariectomy, or “spaying” a mare is considered a last resort for behavioral
modification or estrus suppression. This procedure involves the removal of the ovaries
through various methods including a ventral abdominal incision or flank laparotomy,
laparoscopy, or colpotomy (Ross, 1991; Hooper et al., 1993; Rodgerson et al., 2001).
This method is a permanent procedure, thus eliminating any future reproductive potential.
A common misconception regarding ovariectomy is the complete removal of
unwanted behavior or that mare’s behavior will be similar to her behavior after
exogenous hormones (McCue, 2003). Again, mares differ from other animals due to the
fact that not all of their hormone driven behavior originates from ovarian derived
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estrogen. Mares can display “paradoxical” estrous behavior even during seasonally
anovulatory periods as well as after ovariectomy. This phenomenon occurs as a result of
hormone secretion from the adrenal cortex (Asa et al., 1980). This is an important factor
to consider when evaluating ovariectomy.
In a study by Jorgensen et al. (1996), they found that ovariectomy was utilized by
44% of respondents, and 60.5% of respondents reported an improvement of behavior in
80% or more of treated mares. Forty-five percent of owners and trainers reported 80% or
better improvement in athletic performance in ovariectomized mares. These results are
much better than scientific reports that show 30% or more of ovariectomized mares
continue to display some form of behavioral estrus. It is important to note that low
progesterone is all that is needed for a mare to display estrus and estrogen intensifies
estrus, but is not always needed. Thus, if a mare’s behavioral issues are truly associated
with estrus, ovariectomy could have the opposite effect and make the behavior of the
mare worse (Pryor and Tibary, 2005).
The best option for determining if ovariectomy should be performed is the
observation of behavior during the winter anestrus period when mare’s hormone
production and ovarian function are very minimal. Observations during this period could
allow options to be carefully weighed and the origin of the mare’s behavior to be better
understood prior to undergoing a permanent procedure.
Oxytocin Treatment

Thus far, this review has covered many of the general methods of estrus
suppression. These have all fallen into the categories of hormonal, surgical, and
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immunological methods. Most of the methods reviewed in the hormonal category are
methods used specifically to prolong the function of the CL on the ovary, thus the natural
secretion of progesterone occurs, suppressing estrus naturally. The methods already
discussed that fall in the category of prolonged CL function include the use of an
intrauterine glass ball, pregnancy, infusion of plant oils, and induction of a late diestrus
ovulation. The advantages and disadvantages have been discussed, however, there is
need for another method of prolonged CL function that is safe, reliable, effective, and
easily reversible.
The administration of exogenous oxytocin during the diestrus period is a
promising alternative method of blocking luteolysis in order to prolong the function of
the CL. As discussed previously, endogenous oxytocin secretion plays an important role
in luteolysis, regulating the secretion of PGF2α from the endometrium during luteolysis
in mares (Vanderwall et al., 1998; Shand et al., 2000). Research has discovered that
administration of exogenous oxytocin to mares near the time of luteolysis (days 11-15
after ovulation) induces the onset of PGF2α secretion, however, if oxytocin is
administered prior to day 10 post-ovulation, the opposite effect occurs and PGF2α is not
secreted, luteolysis is disrupted, and the CL remains intact for a prolonged period of time
(Betteridge et al., 1985; Goff et al., 1987; Starbuck et al., 1998). Further research of
oxytocin occurred with the continuous infusion of oxytocin using an osmotic minipump
inserted subcutaneously into the mare. The infusion of 5 µl h-1 went from days 8-20 postovulation and resulted in prolonged diestrus in four out of five mares versus all four
control mares that were administered saline and underwent luteolysis at the expected
time. When the infusion via the minipump began on day 10, prolonged diestrus occurred

40
in three out of five mares and in the two mares without prolonged CL function, luteolysis
was induced immediately. Luteolysis occurred at the expected time in the four control
mares infused with saline (Stout et al., 1999). This method worked, however, the
continuous nature of treatment was impractical as a long-term method for the suppression
of estrus.
In an effort to avoid continuous infusion, Vanderwall et al. (2007b) conducted a
study in which six mares were treated with 60 units (3 mL) of oxytocin, IM, twice daily
on days 7 to 14 after ovulation. Six control mares were administered the same volume of
saline. This proved effective; with prolonged CL function being observed through day 30
in all the treated mares whereas all control mares underwent luteolysis by day 16 of their
cycle. It was then hypothesized that a once-daily injection of oxytocin would be as
effective as the twice-daily protocol. Once-daily injections would greatly simplify the
protocol for veterinarians and owners. In a subsequent study by Vanderwall et al.,
(2012b) the same 60-unit dose of oxytocin was administered twice daily to seven mares
and once daily to eight mares. The occurrence of prolonged CL function was five of
seven mares (71%), five of eight mares (63%) respectively, while one of seven (14%) of
control mares displayed spontaneously prolonged CL function. No difference (P > 0.05)
was found in the proportion of mares with prolonged CL function between the once daily
and twice daily oxytocin treatments. It was concluded that the administration of oxytocin
could be reduced from twice to once daily and still remain effective.
In another study, Vanderwall et al. (2012a) again designed a study around the use
of oxytocin to suppress estrus. In this particular protocol, the once daily administration
of 60 units of oxytocin was given on days 7 to 14 post-ovulation. The objective was to

41
monitor duration of CL function and estrous behavior in mares for 90 days after
administration. Two of the nine control mares (22%) had spontaneously prolonged CL
function whereas six of the nine oxytocin-treated (67%) also had prolonged CL function
(P = 0.08). The control mares that displayed spontaneous prolonged CL function had a
mean duration of CL function of 78 days. The six treatment mares had a mean duration
of CL function of 69 days. The mares in the control group and one of the mares in the
treatment group with prolonged CL function did not display estrous behavior during the
time their plasma progesterone remained above 1.0 ng/mL. Interestingly, the remaining
five treatment mares with prolonged CL function did display weak estrus occasionally
during a period of elevated progesterone. It was concluded that the oxytocin treatment
works for approximately two months in two thirds of treated mares.
Other groups have tried the oxytocin protocol with altered dose and route of
administration, as well as duration of treatment. Gee et al. (2012) reported that five of six
mares (83%) treated with 10 units of oxytocin intravenously (IV) once daily also on days
7-14 displayed prolonged CL function compared to one of the six (17%) mares treated
with 10 units intramuscularly, and two of the (33%) mares treated with saline
intramuscularly. This data combined with the previously discussed data indicates that the
dose of 10 units of oxytocin administered intramuscularly does not prolong CL function
and the threshold for an intramuscular dose to disrupt luteolysis is between 10 and 60
units of oxytocin. In all of the mares with prolonged CL function, estrous behavior was
inhibited, which demonstrates the effectiveness of administration of oxytocin for estrus
suppression. Discovering the threshold for intramuscular injections is important for
keeping the protocol user friendly for horse owners.

42
In a 2013 study by Keith et al., three different durations of oxytocin treatment
were examined. Sixty units of oxytocin were administered intramuscularly on day 8 and
then the three different durations of treatment (2, 4, or 6 days). Administration of
oxytocin on days 8 to 10, 8 to 12, an 8 to 14 resulted in prolonged CL function in three of
seven (43%), four of seven (57%), and six of seven (86%) of mares, respectively. None
of the control mares displayed any prolonged luteal function. These results showed that
the proportion of mares with prolonged CL function was increased as treatment days
increased, thus confirming that the most effective treatment time for oxytocin is from
days 8 to 14, or the expected time of luteolysis.
In one study, the synthetic oxytocin analog known as carbetocin was administered
to mares on days 7 to 14 post-ovulation and compared to another group of oxytocin
treated mares for the same duration. The oxytocin treated mares were administered 60
units of oxytocin intramuscularly, once daily. The carbetocin treated mares were
administered the equivalent dose of 1.19 mg carbetocin intramuscularly, once daily on
days 7 to 14. The administration of oxytocin increased the inter-ovulatory interval (P <
0.01) while the carbetocin decreased the inter-ovulatory interval (P>0.01) and essential
“short-cycled” the mares. It was concluded that the use of carbetocin in this dose,
treatment, and schedule was not effective in prolonging CL function (Bare et al., 2013).
Previously in this review, the role of oxytocin in luteolysis was addressed. It is
known that the ability of the endometrium to secrete PGF2α in response to either
exogenous or endogenous oxytocin increases between days 10-15 after ovulation. This
sensitivity is related to the rise of oxytocin receptors as well as enzymes needed for
PGF2α synthesis. Before day 10, these same receptors and enzymes are low which plays
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a role in the ability of oxytocin to influence PGF2α secretion. In an effort to understand
the mechanism of action of exogenous oxytocin, Vanderwall et al. (2012b) tested the
hypothesis that the effectiveness of the administration of oxytocin on days 7 to 14 of the
estrous cycle was effective in preventing luteolysis by inhibiting the rise of endometrial
oxytocin receptor concentration. It was found that no difference in endometrial oxytocin
receptor concentration existed between treatment and control mares, thus further research
was needed to determine the actual mechanism of action. In 2013, Keith et al. published
a study examining the same hypothesis, however, they were successful in determining
why the oxytocin protocol was effective. It was found that oxytocin treatment suppresses
PGF2α secretion by preventing the upregulation of the gene expression of COX-2 in the
endometrium, as previously mentioned in this review.
The body of research on the topic of administration of exogenous oxytocin to
suppress estrus in mares is convincing and supports the use of 60 units of oxytocin on
days 7 or 8, to 14 post-ovulation and the subsequent disruption of luteolysis. Numerous
studies by Vanderwall (2013) have shown the progression of frequency, duration, and
mechanism of oxytocin treatments and their effect on prolonging the CL. The
administration of exogenous oxytocin and its ability to prolong CL function with the
release of progesterone naturally is advantageous to veterinarians, horse owners, and
trainers.
The largest disadvantage to the current oxytocin protocol is the need for detection
of day 0 or day of ovulation in order to then begin the treatments on day 7 of the mare’s
cycle. Detecting ovulation must be done by a veterinarian via transrectal palpation and
ultrasound. Multiple trips to the veterinarian in order to establish ovulation are usually

44
needed, and the costs and effort incurred with such visits can be a disadvantage. In an
effort to address this issue, we hypothesized that by extending the duration of oxytocin
administration, treatment could be initiated at any point during the estrous cycle (i.e.,
without knowing the day of ovulation) and still effectively prolong CL function.
Therefore, the objective of this study was to determine if treating mares with oxytocin
daily for 29 days would result in prolonged CL function.
MATERIALS AND METHODS
Animals
This study was conducted in the Northern Hemisphere under natural photoperiod
using 17 Quarter Horse-type mares that were between 2 and 17 years old and weighed
300 to 500 kg. All animal procedures were approved and conducted following the
guidelines of the Utah State University Institutional Animal Care and Use Committee
(IACUC). The reproductive tract of each mare was examined with transrectal palpation
and ultrasound in April and/or May to confirm that spontaneous seasonal ovulatory
activity had commenced (i.e., a CL was identified). All of the mares had ovulated by late
May. Prior to the study, no reproductive hormones were administered to any of the
mares to regulate their cyclical reproductive activity (i.e., they were allowed to cycle
spontaneously without hormonal manipulation). After confirming spontaneous ovulatory
activity in all of the mares, no further reproductive examinations were performed for the
duration of the study period.
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Experimental Protocol

Mares were randomly assigned to two groups: 1) saline-treated control (n=8) and
2) oxytocin-treated (n=9).

Prior to initiating treatment, 10 cc of jugular blood was

collected from each mare three times weekly (M, W, F) for three weeks. This was done
to determine, based upon blood progesterone concentration, whether any mares had
spontaneously prolonged CL function before treatment was initiated (i.e., blood
progesterone remaining >1.0 ng/mL continuously throughout the pretreatment period).
Mares that displayed evidence of spontaneously prolonged CL function during the
pretreatment period were removed from the study. At the end of the pretreatment period
(day 1), control mares began receiving 3 cc of sterile saline IM once daily and the
oxytocin-treated mares began receiving 60 units (3cc) oxytocin IM, and those treatments
were continued through day 29. Starting on day 1, jugular blood samples were collected
daily for 7 days, and then three times weekly (M, W, F) for the duration of the study
period (day 80). Blood samples were allowed to clot at room temperature, after which
the serum was recovered and kept frozen at -20°C until progesterone was measured.
Mares were considered to have prolonged CL function if serum progesterone levels
remained >1.0 ng/mL for at least 30 days during and/or after the treatment period.
Progesterone Assay
Progesterone was measured using a commercially available kit (Immulite
Progesterone, Siemens, Malvern, PA, USA) designed for an enzyme-amplified
chemiluminescence assay system (Immulite 1000, Diagnostic Products Corporation, Los
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Angeles, CA, USA) and performed according to the manufacturer’s protocol. The intraassay coefficient of variance was 8.6% and the inter-assay coefficient of variance was
10.2%. The sensitivity of the assay was 0.2 ng/mL; values below the assay sensitivity
were assigned a value equal to the sensitivity.
Statistical Analysis

The proportion of mares in each group with prolonged CL function was compared
using Fisher’s Exact Test (GraphPad Software, Inc., La Jolla, CA, 92037). A probability
of P < 0.05 was considered significant.
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RESULTS
Pre-Treatment Period
One saline-treated control mare had blood progesterone concentrations that
remained above 1.0 ng/mL continuously throughout the pretreatment period, indicating
spontaneously prolonged CL function (prior to initiating treatment). Therefore, that mare
was removed from the study, leaving seven mares in the control group. The remaining
mares in both treatment groups demonstrated baseline levels of progesterone at least once
during the pretreatment period, indicating they had undergone luteolysis during the 3week period before treatments were initiated, which was taken as evidence of normal
cyclicity.
Treatment Period
One of seven control mares (Figure 4) and seven of nine oxytocin-treated mares
demonstrated prolonged CL function that was initiated during the 29-day treatment
period. The proportion of mares with prolonged CL function was higher in the oxytocintreated group compared to the saline-treated group (7/9 vs. 1/7, respectively; P<0.05).
Three of the seven oxytocin-treated mares that developed prolonged CL function initially
underwent luteolysis within 3 to 7 days following the start of oxytocin treatment, and
then developed prolonged CL function after the subsequent ovulation during the
treatment period (Figure 5). In the other four oxytocin-treated mares that developed
prolonged CL function, progesterone remained >1.0 ng/mL throughout the treatment
period and into the post-treatment period (Figure 5). All mares with prolonged CL
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function maintained elevated blood progesterone concentrations through at least day 56
of the study.

Figure 4. Serum progesterone levels of control mares during and after the treatment
period.
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Figure 5. Serum progesterone levels of oxytocin treated mares during and after the
treatment period.
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DISCUSSION
The results of this study supported the hypothesis that extending the duration of
oxytocin administration allows treatment to be initiated at any point during the estrous
cycle and still effectively prolong CL function. All of the mares with prolonged CL
function maintained blood progesterone concentrations above 1.0 ng/mL for over 50
days, which is a sufficient concentration of progesterone to block estrous behavior (Loy
and Swan, 1966; Hawkins et al., 1979). One control mare (14%) developed
spontaneously prolonged CL function (during the treatment period), which has been
reported to occur in approximately 8 to 10% of estrous cycles during the height of the
physiological breeding season and up to 20 to 25% of estrous cycles during the autumnal
transition into the anovulatory season (King et al., 2010).
In nonpregnant mares, the ability of the endometrium to secrete PGF2α in
response to oxytocin (endogenous or exogenous) increases between days 10 and 15 postovulation as a result of increasing concentrations of endometrial oxytocin receptors
(Sharp et al., 1997; Starbuck et al., 1998) and PGF2α synthetic enzymes (Boerboom, et
α

al., 2004). In contrast, before day 10, endometrial oxytocin receptor concentrations and
PGF2α synthetic enzymes are low (Sharp et al., 1997; Starbuck et al., 1998; Boerboom et
al., 2004), thus blocking the ability of oxytocin to stimulate PGF2α secretion. In a
previous study by Vanderwall et al. (2012b), it was hypothesized that initiating treatment
with oxytocin prior to day 10 post-ovulation prevented subsequent luteolysis by
inhibiting an increase in endometrial oxytocin receptor concentration. However, there
was no difference in endometrial oxytocin receptor concentrations between control and
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oxytocin-treated mares on day 15, so that hypothesis was not supported. Subsequently,
Keith et al. (2013) demonstrated that initiating oxytocin treatment prior to day 10
suppresses PGF2α secretion by preventing upregulation of endometrial gene expression
of cyclooxygenase-2, the key regulatory enzyme in PGF2α synthesis/secretion that
otherwise would be upregulated on days 14 to 15, allowing the onset of PGF2α secretion.
Therefore, the anti-luteolytic effect of exogenous oxytocin occurs “downstream” from its
receptor.
In an effort to simplify the oxytocin treatment protocol by eliminating the need
for detection of ovulation, we extended the treatment period to 29 days and initiated
treatment randomly during the estrous cycle. This was done with the anticipation that
treatment would likely be initiated in some mares on days 10 to 15, which as described
above, would induce PGF2α secretion causing luteolysis to occur. Therefore, the 29-day
period of treatment was designed to ensure continued treatment of mares in which
luteolysis was induced for a long enough period such that after they underwent luteolysis,
they would still be receiving oxytocin on the critical days (days 7 to 14) of the following
cycle. As these results demonstrated, three of the seven mares that displayed prolonged
luteal function initially underwent luteolysis and then subsequently developed prolonged
CL function. The other four mares in the treatment group that had prolonged CL function
must have received oxytocin treatments beginning prior to day 10 of their cycle, since
they did not undergo luteolysis immediately following the start of oxytocin treatment.
In conclusion, the results of this study demonstrated the effectiveness of chronic
oxytocin treatment; initiated randomly during the estrous cycle, for prolonging CL
function CL in mares.
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CONCLUSIONS
The suppression of estrus in mares is a growing trend and is important to the
equine industry. Mares are frequently used and the variable behavior and performance
related to the estrous cycle is frustrating and costly. Over the course of the last decade,
research has developed various methods to suppress estrus and the use of exogenous
oxytocin appears to be effective and significant. The 29-day oxytocin protocol addresses
issues previously discussed regarding the growing scrutiny of administering synthetic
progestins to performance animals and issues with safety for personnel handling
hormones. Another advantage of exogenous oxytocin is the easy reversal of the state of
prolonged luteal function with a luteolytic dose of PGF2α, which will allow the mare to
return to normal cyclicity. The oxytocin protocol is also advantageous because of the
low cost of materials, as opposed to synthetic progesterone/progestins. This is of great
advantage to the consumer, whereas orally active altrenogest can be expensive and
needed long term. The greatest advantage to this protocol exists in the elimination of
frequent and expensive trips to a veterinarian. Reducing these trips and the ease of
administration of oxytocin in an IM dose presents a method to a consumer that is safe,
effective, and inexpensive. Disadvantages do occur, however, and the multiple injections
can be difficult with mares that have an aversion to needles, though most of the mares in
the study tolerated needles well. Mares are frequently used in the performance industry
and much time, training, and expense is invested in these animals. Suppressing estrus
using exogenous oxytocin is an effective and desirable method that will allow horse
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owners, trainers, and veterinarians to be successful in the showing and use of these
animals.
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